Therapeutic nanosystems co-deliver anticancer drugs and oncogene SiRNA to achieve synergetic precise cancer chemo-gene therapy

Liang, Yuanwei; Sang, Chengcheng; Mei, Chaoming; Li, Xiaoling; Chen, Tianfeng

doi:10.1039/c8tb00004b

Cited by 19 publications

(18 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the stability of particles under X-ray irradiation was analyzed by comparing the size and UV absorption before and after X-ray irradiation (4 Gy). 59 Additionally, four samples of GTe/GTe-RGD were dispersed in PBS (pH 7.4), GSH (10 mM), PBS (pH 5.3), and GSH (pH 5.3) solutions, respectively. After treatment for 24 h, the morphologies of these samples were assessed by TEM.…”

Section: Stability and Hemolysis Analysis Stability Analysismentioning

confidence: 99%

Triangle-Shaped Tellurium Nanostars Potentiate Radiotherapy by Boosting Checkpoint Blockade Immunotherapy

Huang

Ouyang

et al. 2020

Matter

Self Cite

View full text Add to dashboard Cite

Section: Stability and Hemolysis Analysis Stability Analysismentioning

confidence: 99%

Triangle-Shaped Tellurium Nanostars Potentiate Radiotherapy by Boosting Checkpoint Blockade Immunotherapy

Huang

Ouyang

et al. 2020

Matter

Self Cite

View full text Add to dashboard Cite

“…For instance, loaded MGMT-siRNA liposomes have been tested in GBM treatment resulting in MGMT downregulation, DNA repair induction, and decreased drug efflux capacities responsible for increasing GBM cell sensitivity to TMZ [164]. In another study, RGD-functionalized pH-responsive polyamidoamine (PAMAM) dendrimers were investigated for delivery of both c-myc siRNA anddoxorubicin (DOX)-loaded Se NP in GBM therapy [165]. The RGD functionalization of PAMAM enhances the uptake of siRNA dendrimers by cancer cells [165].…”

Section: Innovative Treatments For Glioblastomamentioning

confidence: 99%

Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment

et al. 2022

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a grade IV glioma considered the most fatal cancer of the central nervous system (CNS), with less than a 5% survival rate after five years. The tumor heterogeneity, the high infiltrative behavior of its cells, and the blood–brain barrier (BBB) that limits the access of therapeutic drugs to the brain are the main reasons hampering the current standard treatment efficiency. Following the tumor resection, the infiltrative remaining GBM cells, which are resistant to chemotherapy and radiotherapy, can further invade the surrounding brain parenchyma. Consequently, the development of new strategies to treat parenchyma-infiltrating GBM cells, such as vaccines, nanotherapies, and tumor cells traps including drug delivery systems, is required. For example, the chemoattractant CXCL12, by binding to its CXCR4 receptor, activates signaling pathways that play a critical role in tumor progression and invasion, making it an interesting therapeutic target to properly control the direction of GBM cell migration for treatment proposes. Moreover, the interstitial fluid flow (IFF) is also implicated in increasing the GBM cell migration through the activation of the CXCL12-CXCR4 signaling pathway. However, due to its complex and variable nature, the influence of the IFF on the efficiency of drug delivery systems is not well understood yet. Therefore, this review discusses novel drug delivery strategies to overcome the GBM treatment limitations, focusing on chemokines such as CXCL12 as an innovative approach to reverse the migration of infiltrated GBM. Furthermore, recent developments regarding in vitro 3D culture systems aiming to mimic the dynamic peritumoral environment for the optimization of new drug delivery technologies are highlighted.

show abstract

“…In a similar one‐pot synthesis design, a selenium‐based inorganic nanoparticle was developed to co‐deliver c‐myc siRNA and Dox. [ 153 ] Dox, vitamin C, and Na 2 SeO 3 were first mixed together to form Dox‐embedded selenium‐core nanoparticles (SeNP‐Dox), which were then mixed with arginine–glycine–aspartic acid peptide (RGD)‐modified PAMAM to complex with c‐myc siRNA. RGD‐SeNP‐Dox‐siRNA demonstrated a marked ability for penetrating the blood brain barrier and transformed its shape in U251 glioblastoma cells’ lysosomes for precise payload release.…”

Section: Combinatorial Delivery Of Gene–chemo Therapeutics By Inorganmentioning

confidence: 99%

“…In a similar one-pot synthesis design, a selenium-based inorganic nanoparticle was developed to co-deliver c-myc siRNA and Dox. [153] Dox, vitamin C, and Na 2 SeO 3 were first mixed together to form Dox-embedded selenium-core nanoparticles (SeNP-Dox), which were then mixed Figure 6. Inorganic nanoparticle-mediated co-delivery of tumor-suppressing nucleic acids and chemotherapeutics.…”

Section: (14 Of 34)mentioning

confidence: 99%

Inorganic Nanomaterial‐Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities

Lin

Revia

Zhang

2020

Adv Funct Materials

View full text Add to dashboard Cite

Cancer is a genetic disease originating from the accumulation of gene mutations in a cellular subpopulation. Although many therapeutic approaches have been developed to treat cancer, recent studies have revealed an irrefutable challenge that tumors evolve defenses against some therapies. Gene therapy may prove to be the ultimate panacea for cancer by correcting the fundamental genetic errors in tumors. The engineering of nanoscale inorganic carriers of cancer therapeutics has shown promising results in the efficacious and safe delivery of nucleic acids to treat oncological diseases in small‐animal models. When these nanocarriers are used for co‐delivery of gene therapeutics along with auxiliary treatments, the synergistic combination of therapies often leads to an amplified health benefit. In this review, an overview of the inorganic nanomaterials developed for combinatorial therapies of gene and other treatment modalities is presented. First, the main principles of using nucleic acids as therapeutics, inorganic nanocarriers for medical applications and delivery of gene/drug payloads are introduced. Next, the utility of recently developed inorganic nanomaterials in different combinations of gene therapy with each of chemo, immune, hyperthermal, and radio therapy is examined. Finally, current challenges in the clinical translation of inorganic nanomaterial‐mediated therapies are presented and outlooks for the field are provided.

show abstract

Therapeutic nanosystems co-deliver anticancer drugs and oncogene SiRNA to achieve synergetic precise cancer chemo-gene therapy

Abstract: Herein we design a therapeutic nanoplatform as carriers of oncogene siRNA and chemotherapeutics to achieve precise cancer therapy.

Cited by 19 publications

References 53 publications

Triangle-Shaped Tellurium Nanostars Potentiate Radiotherapy by Boosting Checkpoint Blockade Immunotherapy

Triangle-Shaped Tellurium Nanostars Potentiate Radiotherapy by Boosting Checkpoint Blockade Immunotherapy

Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment

Inorganic Nanomaterial‐Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities

Contact Info

Product

Resources

About